• Sugarbud Craft Growers (SUGR) has announced key financial and operating results for the three months ended March 31, 2022
  • The company anticipates announcing its first quarter 2022 financial statements after-market on Monday, May 30, 2022
  • Sugarbud expects to record gross revenue of between $925,000-$950,000 in Q1 2022, representing a 25 per cent increase over Q4, 2021
  • The company expects to record shipments of between 150,000 – 160,000 grams of dried cannabis in Q1 2022, a year over year increase of over 90 per cent vs Q1 2021
  • Sugarbud is a leading craft cannabis company focused on the cultivation and production of cannabis products
  • Sugarbud Craft Growers Corp. (SUGR) opened trading at C$0.55 per share

Sugarbud Craft Growers (SUGR) has announced key financial and operating results for the three months ended March 31, 2022.

The company anticipates announcing its first quarter 2022 financial statements and management’s discussion and analysis after-market on Monday, May 30, 2022.

Q1 2022 highlights

  • Revenue growth
    Sugarbud expects to record gross revenue of between $925,000-$950,000 in Q1 2022, representing a 25 per cent increase over Q4, 2021 and a 37 per cent year over year increase vs Q1 2021.
  • Record grams sold
    The company expects to record shipments of between 150,000 – 160,000 grams of dried cannabis in Q1 2022, representing a sequential increase of over 10 per cent vs. Q4 2021 and a year over year increase of over 90 per cent vs Q1 2021.

Sugarbud is a leading craft cannabis company focused on the cultivation and production of cannabis products.

Sugarbud Craft Growers Corp. (SUGR) opened trading at C$0.55 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.